Trial Profile
A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 22 Feb 2024 Planned End Date changed from 5 Feb 2024 to 12 Mar 2024.
- 06 Mar 2023 Planned End Date changed from 3 Feb 2023 to 5 Feb 2024.
- 04 Aug 2021 Planned End Date changed from 4 Feb 2022 to 3 Feb 2023.